Metal Tiger confirms exciting new mineralisation zone in Botswana

Andrew Schonberg Sharecast | 17 Feb, 2017 12:02 | | |

metal tiger
  • 2.15
  • -3.37%-0.08
  • Max: 2.30
  • Min: 2.05
  • Volume: 9,939,857
  • MM 200 : n/a
10:20 20/02/17
  • 9,808.16
  • 0.37%36.18
  • Max: 9,834.51
  • Min: 9,770.51
  • Volume: 0
  • MM 200 : n/a
10:50 20/02/17
  • 907.00
  • -0.10%-0.94
  • Max: 908.66
  • Min: 906.17
  • Volume: 0
  • MM 200 : n/a
10:50 20/02/17
  • 0.00
  • 0.00%0.00
  • Max: 0.00
  • Min: 0.00
  • Volume: 0
  • MM 200 : n/a
05:36 20/02/17

Shares in Metal Tiger are down more than 16% despite it confirming the discovery of an "exciting new zone of mineralisation" beneath the T3 Resource, in Botswana's Kalahari Copper Belt.

"We think that this new discovery has the potential to significantly improve the dynamics and economics of the T3 Deposit," said chief executive Michael McNeilly, referring to the joint-venture project with partner MOD Resources.

The new zone comprised multiple intervals of copper sulphide mineralisation over 75m.

Metal Tiger anticipated assay results could be the most significant since the T3 discovery hole last March, 52m @ 2% copper and 32g/t silver.

"This previously unknown new zone of mineralisation was discovered during the T3 Resource infill drilling being conducted as part of the current Prefeasibility Study works," it said.

Concurrent to the infill drilling, Metal Tiger said the ongoing IP geophysics survey work had identified several new anomalies that could be related to sulphide mineralisation in the vicinity of the T3 Deposit.

"The first of these new deep anomalies is currently being drilled and we look forward to the findings."

At 11:48 GMT, shares in AIM-priced Metal Tiger were down 16.22% to 2.32p each.

More news

10:44 Analysts say RBS's new plans bring dividend closer, lift earnings potential

If Royal Bank of Scotland retains the Williams & Glyn business, as proposed, it will bring a return to dividends closer and lift earnings in 2019, according to analysts at Morgan Stanley, JP Morgan Cazenove and others on Monday.

10:39 Kraft Heinz ditches Unilever takeover plans

Kraft Heinz has ditched its plans to take over Unilever, just two days after it emerged the London-listed consumer goods giant had rejected a $143bn offer.

10:37 Beowulf Mining says no news on Kallak North

Beowulf Mining noted the recent rise in its share price and comments over the weekend by the chief mining inspector in Finland, who said she hoped there would be clarity this week over which direction the process for the award of the exploitation concession for Kallak North was heading.

10:35 Condor Gold planning £5.24m fundraising to develop Nicaragua mine

Condor Gold plans to raise £5.24m in share placing and director's subscription to further develop its mine in Nicaragua.

10:29 Proactis Holdings anticipates a 36% rise in H1 revenue

AIM-listed procurement solution provider Proactis Holdings anticipates that results for the first half of the year will be in line with expectations with a rise in revenue.

10:22 BGEO Group rapid profits growth slowed by Georgian currency slide

BGEO Group, the Georgian banking and healthcare group, revealed 2016 profits and earnings rose strongly even though they were held back by a decline in the fourth-quarter.

10:22 JP Morgan downgrades StanChart, saying imperfect play on US rates

Analysts at JP Morgan downgraded their recommendation on StanChart stock, emphasising that its shares were an "imperfect play" on the US interest rate cycle and how the 'bullish' scenario for the shares required a medium-term perspective.

10:19 WPP buys stake in Ireland's Eightytwenty

WPP’s marketing communications network, Ogilvy & Mather, has acquired a stake in its digital partner in Ireland, Eightytwenty.

10:07 One Media considers options after court vacates infringement judgement

Digital media content provider One Media iP Group updated the market on its claims in the US that its music rights had been exploited without authorisation.

10:07 Ergomed's Swedish drug development partner raises £2.9m

AIM-listed pharmaceutical Ergomed’s Stockholm-based development partner Modus Therapeutics has raised £2.9m (32m Swedish krona) to support a phase two study of a sickle cell drug.